Invivyd (IVVD) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Invivyd (NASDAQ: IVVD) is set to release its Q2 2025 earnings results on Wednesday, August 13th, with analysts expecting a loss of ($0.04) per share and revenue of $23.16 million.
• In its previous earnings report, Invivyd missed the consensus estimate, reporting ($0.14) EPS and revenue of only $11.30 million, significantly below expectations.
• Analysts from HC Wainwright and D. Boral Capital have reiterated a "buy" rating for Invivyd, with price targets set at $5.00 and $9.00, respectively.

Invivyd (NASDAQ:IVVD - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $23.16 million for the quarter.

Invivyd (NASDAQ:IVVD - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.10). The company had revenue of $11.30 million for the quarter, compared to analyst estimates of $34.45 million. Invivyd had a negative net margin of 389.01% and a negative return on equity of 165.24%. On average, analysts expect Invivyd to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Invivyd Price Performance

Shares of NASDAQ IVVD traded up $0.04 during trading hours on Friday, hitting $0.80. 698,019 shares of the stock were exchanged, compared to its average volume of 731,888. Invivyd has a one year low of $0.35 and a one year high of $2.74. The company's 50 day moving average is $0.78 and its 200 day moving average is $0.82.

Institutional Investors Weigh In On Invivyd

An institutional investor recently raised its position in Invivyd stock. Invesco Ltd. grew its holdings in Invivyd, Inc. (NASDAQ:IVVD - Free Report) by 190.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 108,999 shares of the company's stock after acquiring an additional 71,485 shares during the quarter. Invesco Ltd. owned 0.09% of Invivyd worth $66,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 70.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. D. Boral Capital restated a "buy" rating and set a $9.00 price target on shares of Invivyd in a report on Thursday, June 26th. HC Wainwright restated a "buy" rating and set a $5.00 target price on shares of Invivyd in a research note on Thursday, June 26th.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.